Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Whi-P131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 known ✓ | P52333 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | RET | P07949 | 6/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 1/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 5/20 | 0.97 |
| ▸ | KIF5B | P33176 | 4/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.75 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Whi-P131 SCHEMBL29369589 | 1.00 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| Whi-P131 SCHEMBL6068752 | 0.99 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| SCHEMBL20792806 | 0.93 | EGFR (0.87) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5472599 | 0.87 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| SCHEMBL3533221 | 0.87 | EGFR (0.80) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5473778 | 0.87 | EGFR (0.80) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5467825 | 0.87 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| SCHEMBL4477758 | 0.86 | EGFR (0.77) | EGFRKDRRETJAK3GAK | |
| SCHEMBL22299727 | 0.86 | EGFR (0.76) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5477771 | 0.86 | KDR (1.00) | EGFRKDRRETJAK3GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2332 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-12138490-B2 | Methods for treating hair loss disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-12 | — | — | US | claimed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | claimed |
| US-20230285401-A1 | Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-20230158032-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Universitätsklinikum Jena (DE) | 2023-05-25 | — | — | US | claimed |
| CN-116157131-A | Methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2023-05-23 | — | — | CN | claimed |
| US-20230111697-A1 | METHODS FOR TREATING HAIR LOSS DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-04-13 | — | — | US | claimed |
| WO-2023060234-A1 | SYSTEMS AND METHODS FOR CHARACTERIZING PATHOPHYSIOLOGY | UNIVERSITY OF WASHINGTON (US) | 2023-04-13 | — | — | WO | claimed |
| EP-1105378-A1 | QUINAZOLINE DERIVATIVES | Parker Hughes Institute (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2001036394-A1 | 4-(4'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE TO PREVENT DEVELOPMENT OF COLORECTAL CANCER | PARKER HUGHES INSTITUTE (US) | 2001-05-25 | — | — | WO | claimed |
| EP-1091739-A1 | METHOD FOR INHIBITING C-JUN EXPRESSION USING JAK-3 INHIBITORS | Parker Hughes Institute (US) | 2001-04-18 | — | — | EP | claimed |
| US-6177433-B1 | ADMINISTERING A TYROSINE KINASE INHIBITOR | PARKER HUGHES INSTITUTE | 2001-01-23 | — | — | US | claimed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000051587-A2 | JAK-3 INHIBITORS FOR TREATING ALLERGIC DISORDERS | PARKER HUGHES INSTITUTE (US) | 2000-09-08 | — | — | WO | claimed |
| US-6080747-A | FOR THERAPY AND PROPHYLAXIS OF MAST CELL MEDIATED ALLERGIC REACTIONS | HUGHES INSTITUTE (US) | 2000-06-27 | — | — | US | claimed |
| WO-2000010981-A1 | QUINAZOLINE DERIVATIVES | PARKER HUGHES INSTITUTE (US) | 2000-03-02 | — | — | WO | claimed |
| WO-2000000202-A1 | METHOD FOR INHIBITING C-JUN EXPRESSION USING JAK-3 INHIBITORS | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | claimed |